Industry

The transaction provides liquidity option to existing investors and secures long-term capital to support continued growth. RALEIGH, N.C.–(BUSINESS WIRE)–On February 13, 2026, QHP Capital, L.P. (“QHP”) announced the closing of a $1.1 Billion single-asset continuation vehicle for Azurity Pharmaceuticals, Inc. (“Azurity”). The transaction provides liquidity to existing limited partners while enabling QHP to maintain control … [Read more…]

LOS ANGELES–(BUSINESS WIRE)–Pelage Pharmaceuticals, a clinical-stage regenerative medicine biotechnology company, today announced that its first-in-class approach for treating hair loss with investigational medicine PP405 will be featured in a presentation about advances in the hair loss treatment landscape and regenerative mechanisms on Saturday, March 28th at the American Academy of Dermatology (AAD) Annual Meeting, taking … [Read more…]

Comprehensive analysis of one of the largest datasets with harmonized variant calls from over 8,000 cancer whole genomes enables researchers worldwide to uncover rare drivers, new targets, and AI-ready insights that could reshape precision oncology. SAN DIEGO–(BUSINESS WIRE)–#BroadInstitute–Researchers at Inocras, a bioinformatics-led precision health company harnessing the power of whole-genome sequencing (WGS) data and proprietary … [Read more…]

Preclinical research with VS-7375 in combination with PRMT5 inhibitors demonstrated strong durable tumor regressions in KRAS G12D pancreatic cancer models In preclinical pancreatic, lung, and colorectal cancer models, VS-7375 (dual ON/OFF inhibitor) showed deeper and more sustained tumor regression compared to ON-only G12D or pan-RAS inhibitors BOSTON–(BUSINESS WIRE)–Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed … [Read more…]

CRYSTAL LAKE, Ill.–(BUSINESS WIRE)–AptarGroup, Inc. (NYSE:ATR), a global leader in drug delivery, dosing and protection technologies, and consumer product dispensing, today announced that Gael Touya, a seasoned global executive with more than 30 years of experience at the company, most recently as Aptar Pharma President, has been appointed President and Chief Executive Officer, effective September … [Read more…]

Franklin Templeton specialty investment manager acquires three inpatient rehabilitation facilities on behalf of fund investors SAN MATEO, Calif.–(BUSINESS WIRE)–Franklin Templeton, a global investment leader and its specialist investment manager, Clarion Partners, today announced Clarion Partners Real Estate Income Fund Inc.’s (NASDAQ: CPREX) acquisition of three healthcare real estate properties across Texas, Florida, and Colorado. The … [Read more…]

Brand refresh reflects growing industry focus on protecting patient affordability investments and improving visibility across the Gross-to-Net ecosystem IRVINE, Calif.–(BUSINESS WIRE)–#GTN—RIS Rx today announced a new brand identity and messaging platform reflecting its expanding role in addressing one of the pharmaceutical industry’s most persistent financial and operational challenges: Gross-to-Net (GTN) revenue leakage. The refreshed brand … [Read more…]

Clinical leaders to share actionable insights to help post-acute providers strengthen care processes and improve patient outcomes in value-based care BALTIMORE–(BUSINESS WIRE)–Real Time Medical Systems (Real Time), the industry-leading, KLAS Rated, and HITRUST Certified post-acute analytics solution, announced today its participation in the American Association for Post-Acute Care Nursing (AAPACN) 2026 Conference, taking place March … [Read more…]

Total Expected Revenues from the Three Projects Increase from C$68 Million to C$85 Million TREVIGLIO, Italy & BURLINGTON, Ontario–(BUSINESS WIRE)–An Italian subsidiary of Anaergia Inc. (“Anaergia,” the “Company,” “we,” or “our”) (TSX: ANRG) (OTCQX: ANRGF), Anaergia S.r.l., signed amendments to three previously announced contracts with an entity owned by QGM S.à.r.l. (“QGM”), relating to the … [Read more…]

GENT, Belgium & TOKYO–(BUSINESS WIRE)–#IVD–H.U. Group Holdings Inc., and its wholly owned subsidiary, Fujirebio Holdings, Inc. (hereinafter “Fujirebio”) today announced that Fujirebio Europe N.V. has obtained a CE Certificate of the Lumipulse G NfL Blood assay under the Regulation (EU) 2017/746 on in vitro diagnostic medical devices (IVDR). This CLEIA (chemiluminescent enzyme immunoassay) test allows … [Read more…]